| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 5 | |
| #2 | United States | 4 | |
| #3 | WIPO (World Intellectual Property Organization) | 4 | |
| #4 | Australia | 3 | |
| #5 | Brazil | 3 | |
| #6 | Canada | 3 | |
| #7 | China | 3 | |
| #8 | Republic of Korea | 3 | |
| #9 | Israel | 2 | |
| #10 | Mexico | 2 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Medical preparations | |
| #3 | Organic chemistry methods | |
| #4 | Heterocyclic compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Moolenaar Sytske Hyke | 25 |
| #2 | Van Der Geest Ronald | 18 |
| #3 | Sytske Hyke Moolenaar | 7 |
| #4 | Fernandez Casares Ana | 5 |
| #5 | Ronald Van Der Geest | 5 |
| #6 | Geest Ronald Van Der | 1 |
| Publication | Filing date | Title |
|---|---|---|
| CN111465597A | Edaravone salt | |
| AU2018298431A1 | Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders | |
| MX2019008489A | Treatment comprising oral or gastric administration of edaravone. | |
| BR112019014712A2 | AVERAGE TREATMENT THAT UNDERSTANDS THE ENTERED ADMINISTRATION OF EDARAVONA | |
| CN110381923A | Therapeutic treatment including enteral administration Edaravone |